Trade NTLA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Intellia Therapeutics, Inc. (NTLA) is trading at US$12.78, down 2.55% today as of Aug 28, 13:00 EDT. The company has a market capitalisation of US$1.8B. Over the past 52 weeks, NTLA has traded between US$7.95 and US$28.25. On Syfe you can trade NTLA with $0 commission and add it to your watchlist.
| Previous close | US$13.11 |
|---|---|
| Market cap | US$1.8B |
| 52-week range | US$7.95 – US$28.25 |
| Volume | 2.44M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Year: 2016
--Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating
Jul 9, 4:11 PM · MT Newswires
Intellia Therapeutics Q1 Loss Narrows, Revenue Falls
May 11, 11:48 AM · MT Newswires
Intellia Therapeutics, Inc. (NTLA) stock is trading at US$12.78, -2.55% from the previous close of US$13.11.
The market cap for Intellia Therapeutics, Inc. (NTLA) stock is approximately US$1.8B.
The 52-week high for Intellia Therapeutics, Inc. (NTLA) stock is US$28.25.
The 52-week low for Intellia Therapeutics, Inc. (NTLA) stock is US$7.95.
Intellia Therapeutics, Inc. (NTLA) does not currently pay a dividend.
Stay on top of NTLA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
